Osteoarthritis | Serum Biomarkers | ARGS

Osteoarthritis is a serious disease. It affects more than 300 million people across the world. It’s a leading cause of disability among older adults. Therefore, it has a considerable impact on an individual’s quality of life and a huge economic burden on society.
However, there are currently no approved disease-modifying osteoarthritis drugs (DMOADs) and only symptom relief treatments are available. So there is an unmet need for biomarkers that can accelerate OA drug development by improving the understanding of the mechanism of action and finding the right patients.
We re-developed a highly sensitive and robust sandwich immunoassay, huARGS, for detecting ARGS fragments generated by up-regulated proteases, ADAMTS-4/-5, during osteoarthritis.
In TNF-α plus oncostatin M co-incubated human articular cartilage explants, the release of ARGS fragments quantified by huARGS reached a peak at day3, while the release was reduced by an ADAMTS inhibitor. It confirmed the generation of ARGS fragments by ADAMTS-4/-5.
We also measured huARGS biomarker in 20 OA patients’ serum taken throughout the day for diurnal variation, and on three separate days for inter-day variation. Limited inter-day and intra-day variations were observed.
huARGS biomarker was also measured in a subcohort of a placebo-controlled multicenter phase III OA clinical study that aimed to evaluate the safety and efficacy of salmon calcitonin. We investigated the odds ratio (OR) for the radiographic progression over 24 months of the different quartile groups compared to the highest quartile (Q4) group. The participants in the very low group (Q1) were more likely to progress rapidly than the high group. A similar likelihood was not observed in the low group (Q2) and the moderate group.
In conclusion, huARGS biomarker has the potential to aid drug development in various stages, both as a PD biomarker for testing target engagement of ADAMTSs inhibitors, and identifying progressors who might be more likely to respond to a disease-modifying OA drug treatment.
For more information, please visit our website: www.nordicbioscience.com/ther...
Or contact us: www.nordicbioscience.com/contact
***
The information contained in this presentation is for general information purposes only. The information is provided by Nordic Bioscience A/S and while we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the presentation or the information, products, services, or related graphics contained in this presentation for any purpose. Nordic Bioscience A/S does not assume any obligation to update the documents and information available in this presentation. Any reliance you place on the information on the website is therefore strictly at your own risk.
Follow us on our other social media channels to stay informed on the latest news of cutting-edge biomarker research!
LinkedIn: / nordicbioscience
Twitter: / nordic_bio
#nordicbioscience #lifescience #osteoarthritis #biomarkers #proteinfingerprint #extracellularmatrix #ecm